D. D. Bowtell, The genesis and evolution of high-grade serous ovarian cancer, Nat. Rev. Cancer, vol.10, pp.803-808, 2010.

J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers et al., Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012, Int. J. Cancer, vol.136, pp.359-386, 2015.

R. Vang, I. Shih, and R. J. Kurman, Ovarian low-grade and high-grade serous carcinoma: Pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems, Adv. Anat. Pathol, vol.16, pp.267-282, 2009.

I. Shih and R. J. Kurman, Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis, Am. J. Pathol, vol.164, pp.1511-1518, 2004.

J. A. Ledermann, F. A. Raja, C. Fotopoulou, A. Gonzalez-martin, N. Colombo et al., ESMO Guidelines Working Group Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann. Oncol, vol.2013, pp.24-32

R. W. Tothill, A. V. Tinker, J. George, R. Brown, S. B. Fox et al., National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer, version 2, Clin. Cancer Res, vol.14, pp.5198-5208, 2008.

J. Liao, F. Qian, N. Tchabo, P. Mhawech-fauceglia, A. Beck et al., Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism, PLoS ONE, vol.9, 2014.

D. Stark, M. Nankivell, E. Pujade-lauraine, G. Kristensen, L. Elit et al., Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: Quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial, Lancet Oncol, vol.14, pp.236-243, 2013.

L. Ben-fatma, M. Hochlef, O. Gharbi, A. Landolsi, S. Limam et al., Epithelial advanced ovarian carcinoma in the central region of Tunisia: Therapeutic results and prognostic factors on 104 patients, Bull. Cancer, vol.93, pp.1233-1239, 2006.

S. Arai, M. Fanale, S. Devos, A. Engert, T. Illidge et al., Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant, Leuk. Lymphoma, vol.54, pp.2531-2533, 2013.

S. Sasse, B. Klimm, H. Görgen, M. Fuchs, A. Heyden-honerkamp et al., Hodgkin Study Group (GHSG) Comparing long-term toxicity and efficacy of combined modality treatment including extended-or involved-field radiotherapy in early-stage Hodgkin's lymphoma, Ann. Oncol, vol.23, pp.2953-2959, 2012.

K. Behringer, H. Mueller, H. Goergen, I. Thielen, A. D. Eibl et al., Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials, J. Clin. Oncol, vol.31, pp.231-239, 2013.

P. Hanly, I. Soerjomataram, and L. Sharp, Measuring the societal burden of cancer: The cost of lost productivity due to premature cancer-related mortality in Europe, Int. J. Cancer, vol.136, pp.136-145, 2015.

, Int. J. Mol. Sci, vol.19, p.41, 2018.

J. J. Ramsden, MARCKS: A case of molecular exaptation?, Int. J. Biochem. Cell Biol, vol.32, pp.475-479, 2000.

M. Singer, L. D. Martin, B. B. Vargaftig, J. Park, A. D. Gruber et al., A MARCKS-related peptide blocks mucus hypersecretion in a mouse model of asthma, Nat. Med, vol.10, pp.193-196, 2004.

C. C. Ouimet, J. K. Wang, S. I. Walaas, K. A. Albert, and P. Greengard, Localization of the MARCKS (87 kDa) protein, a major specific substrate for protein kinase C, in rat brain, J. Neurosci, vol.10, pp.1683-1698, 1990.

Y. Li, L. D. Martin, G. Spizz, and K. B. Adler, MARCKS protein is a key molecule regulating mucin secretion by human airway epithelial cells in vitro, J. Biol. Chem, vol.276, pp.40982-40990, 2001.

L. H. Allen and A. Aderem, A role for MARCKS, the alpha isozyme of protein kinase C and myosin I in zymosan phagocytosis by macrophages, J. Exp. Med, vol.182, pp.829-840, 1995.

P. J. Blackshear, The MARCKS family of cellular protein kinase C substrates, J. Biol. Chem, vol.268, pp.1501-1504, 1993.

X. Chen and S. A. Rotenberg, PhosphoMARCKS drives motility of mouse melanoma cells, Cell. Signal, vol.22, pp.1097-1103, 2010.

S. Hanada, A. Kakehashi, N. Nishiyama, M. Wei, S. Yamano et al., Myristoylated alanine-rich C-kinase substrate as a prognostic biomarker in human primary lung squamous cell carcinoma, Cancer Biomark, vol.13, pp.289-298, 2013.

K. Rombouts, V. Carloni, T. Mello, S. Omenetti, S. Galastri et al., Myristoylated Alanine-Rich protein Kinase C Substrate (MARCKS) expression modulates the metastatic phenotype in human and murine colon carcinoma in vitro and in vivo, Cancer Lett, vol.333, pp.244-252, 2013.

A. Techasen, W. Loilome, N. Namwat, E. Takahashi, E. Sugihara et al., Myristoylated alanine-rich C kinase substrate phosphorylation promotes cholangiocarcinoma cell migration and metastasis via the protein kinase C-dependent pathway, Cancer Sci, vol.101, pp.658-665, 2010.

Y. Yang, Y. Chen, M. N. Saha, J. Chen, K. Evans et al., Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma, Leukemia, vol.29, pp.715-726, 2015.

Z. Yang, S. Xu, P. Jin, X. Yang, X. Li et al., MARCKS contributes to stromal cancer-associated fibroblast activation and facilitates ovarian cancer metastasis, Oncotarget, 2016.

C. Chen, S. Statt, C. Chiu, P. Thai, M. Arif et al., Targeting myristoylated alanine-rich C kinase substrate phosphorylation site domain in lung cancer. Mechanisms and therapeutic implications, Am. J. Respir. Crit. Care Med, vol.190, pp.1127-1138, 2014.

C. Chen, P. Thai, K. Yoneda, K. B. Adler, P. Yang et al., A peptide that inhibits function of Myristoylated Alanine-Rich C Kinase Substrate (MARCKS) reduces lung cancer metastasis, Oncogene, vol.33, pp.3696-3706, 2014.

B. C. Browne, F. Hochgräfe, J. Wu, E. K. Millar, J. Barraclough et al., Global characterization of signalling networks associated with tamoxifen resistance in breast cancer, FEBS J, vol.280, pp.5237-5257, 2013.

C. Chen, C. Cheng, Y. Yuan, J. Zhai, M. Arif et al., Elevated MARCKS phosphorylation contributes to unresponsiveness of breast cancer to paclitaxel treatment, Oncotarget, vol.6, pp.15194-15208, 2015.

M. Manai, J. Thomassin-piana, A. Gamoudi, P. Finetti, M. Lopez et al., MARCKS protein overexpression in inflammatory breast cancer, Oncotarget, vol.8, pp.6246-6257, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01787705

E. Dorris, A. O'neill, K. Hanrahan, A. Treacy, and R. W. Watson, MARCKS promotes invasion and is associated with biochemical recurrence in prostate cancer, Oncotarget, vol.8, 2017.

T. D. Rohrbach, R. B. Jones, P. H. Hicks, A. N. Weaver, T. S. Cooper et al., MARCKS phosphorylation is modulated by a peptide mimetic of MARCKS effector domain leading to increased radiation sensitivity in lung cancer cell lines, Oncol. Lett, vol.13, pp.1216-1222, 2017.